Characteristics of pulmonary arterial hypertension in aff ected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2

Chest

Volumn 147, Issue 5, 2015, Pages 1385-1394

  Girerd, Barbara ^a,b,c   Coulet, Florence ^d   Jaïs, Xavier ^a,b,c   Eyries, Mélanie ^d,e,f   Van Der Bruggen, Cathelijne ^g   De Man, Frances ^g   Houweling, Arjan ^h   Dorfmüller, Peter ^a,b,c   Savale, Laurent ^a,b,c   Sitbon, Olivier ^a,b,c   Vonk Noordegraaf, Anton ^g   Soubrier, Florent ^d,e,f   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Universite Paris Sud   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ICAN Institute for Cardiometabolism and Nutrition   (France)

^f Institute OfCardiometabolism and Nutrition   (France)

^g Inst for Cardiovascular Research   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM CHANNEL BLOCKING AGENT; SMAD PROTEIN; BMPR2 PROTEIN, HUMAN;

ADULT; AGE; ANIMAL CELL; ARTICLE; BMPR2 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DRUG RESPONSE; EMBRYO; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; IN VITRO STUDY; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PULMONARY HYPERTENSION; SURVIVAL RATE; GENETICS; MUTATION;

ADULT; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; COHORT STUDIES; FEMALE; HETEROZYGOTE; HUMANS; HYPERTENSION, PULMONARY; MALE; MUTATION;

EID: 84929493674     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0880     Document Type: Article

References (28)

1. GaliéN , Hoeper MM , Humbert M , et al ; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC) ; European Respiratory Society (ERS) ; International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension . Eur Respir J. 2009 ; 34 (6): 1219-1263.
2. GaliéN , Hoeper MM , Humbert M , et al ; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the Europe a n Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 ; 30 (20): 2493-2537.
3. Soubrier F , Chung WK , Machado R , et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 ; 62 (suppl 25): D13-D21.
4. Girerd B , Montani D , Coulet F , et a l. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010 ; 181 (8): 851-861.
5. Elliott CG , Glissmeyer EW , Havlena GT , et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation. 2006 ; 113 (21): 2509-2515.
6. Rosenzweig EB , Morse JH , Knowles JA , et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant. 2008 ; 27 (6): 668-674.
7. Kawab ata M , Chytil A , Moses HL. Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor. J Biol Chem. 1995 ; 270 (10): 5625-5630.
8. Liu F , Ventura F , Doody J , MassaguéJ. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 1995 ; 15 (7): 3479-3486.
9. Nohe A , Hassel S , Ehrlich M , et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines diff erent BMP-2 signaling pathways. J Biol Chem. 2002 ; 277 (7): 5330-5338.
10. Nishihara A , Watabe T , Imamura T , Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Bio l Cell. 2002 ; 13 (9): 3055-3063
11. Sitbon O,Humbert M,Jaïs X,et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation. 2005 111 23 3105-3111.
12. Sitbon O , Humbert M , Nunes H , et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40 (4): 780-788.
13. Kovacs G , Avian A , Olschewski A , Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J. 2013 ; 42 (6): 1586-1594.
14. Montani D , Savale L , Natali D , et al. Long-term response to calciu m-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010 ; 31 (15): 1898-1907.
15. McGoon M , Gutterman D , Steen V , et al ; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126 (1-suppl): 14S-34S.
16. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med. 2013 ; 369 (4): 351-361.
17. Austin ED , Ma L , LeDuc C , et al. Whole exome sequencing to identify a n ovel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012 ; 5 (3): 336-343.
18. Hanyu A , Ishidou Y , Ebisawa T , Shimanuki T , Imamura T , M iyazono K. The N domain of Smad7 is essential for specifi c inhibition of transforming growth factor-beta signaling. J Cell Biol. 2001 ; 155 (6): 1017-1027.
19. Rudarakanchana N, Flanagan JA, Chen H, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002 ; 11 (13): 1517-1525.
20. Korchynskyi O , ten Dijke P. Identifi cation and functional characterization of distinct critically important bone morphogenetic protein-specifi c response elements in the Id1 promoter. J Biol Chem. 2002 ; 277 (7): 4883-4891.
21. Pfarr N , Szamalek-Hoegel J , Fischer C , et al. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res. 2011 ; 12 : 99.
22. Sztrymf B , Coulet F , Girerd B , et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med. 2008 ; 177 (12): 1377-1383.
23. Yang X , Long L , Southwood M , et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005 ; 96 (10): 1053-1063.
24. Foletta VC , Lim MA , Soosairajah J , et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol. 2003 ; 162 (6): 1089-1098.
25. Wong WKP , Knowles JA , Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2005 ; 33 (5): 438-446.
26. Machado RD , Rudarakanchana N , Atkinson C , et al. Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specifi c and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2003 ; 12 (24): 3277-3286.
27. Chan MC , Nguyen PH , Davis BN , et al. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol Cell Biol. 2007 ; 27 (16): 5776-5789.
28. Leyton PA , Beppu H , Pappas A , et al. Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specifi c gain of function. PL oS ONE. 2013 ; 8 (10): e76947.